Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice

Abstract Background Current therapies fail to cure over a third of osteosarcoma patients and around three quarters of those with metastatic disease. “Smac mimetics” (also known as “IAP antagonists”) are a new class of anti-cancer agents. Previous work revealed that cells from murine osteosarcomas we...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Tanmay M. Shekhar, Ingrid J. G. Burvenich, Michael A. Harris, Angela Rigopoulos, Damien Zanker, Alex Spurling, Belinda S. Parker, Carl R. Walkley, Andrew M. Scott, Christine J. Hawkins
Format: Artigo
Langue:Inglês
Publié: BMC 2019-09-01
Collection:BMC Cancer
Sujets:
Osteosarcoma
Bone cancer
Sarcoma
Smac mimetic
IAP antagonist
Metastasis
Accès en ligne:http://link.springer.com/article/10.1186/s12885-019-6103-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires